Evidence map›Paper›PMID 40897896›Full record

ArticleNature immunology2025

Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity.

Junko Sawada, Yasuhiro Kikuchi, Maxwell Duah, Jose Luis Herrera, Fumiaki Kanamori, Krisztian Csomos, Tomoko Stansel, Nobuyoshi Hiraoka, Masayuki Yoshida, Jolan Walter and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Biomimetic delivery of a STING agonistMaterials today. Bio · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Diagnostics (Basel, Switzerland) · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Lymphotoxin-driven cancer cell eradication by tumoricidal CD8bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Junko Sawada *Cancer and Blood Disorders Institute, Institute for Fundamental Biomedical Research, and Department of Surgery, Johns Hopkins All Children's Hospital, and Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, St. Petersburg, FL, USA.ORCID http://orcid.org/0000-0001-9100-7037
Yasuhiro Kikuchi *Cancer and Blood Disorders Institute, Institute for Fundamental Biomedical Research, and Department of Surgery, Johns Hopkins All Children's Hospital, and Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, St. Petersburg, FL, USA.ORCID http://orcid.org/0009-0007-7210-3825
Maxwell DuahCancer and Blood Disorders Institute, Institute for Fundamental Biomedical Research, and Department of Surgery, Johns Hopkins All Children's Hospital, and Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, St. Petersburg, FL, USA.
Jose Luis HerreraCancer and Blood Disorders Institute, Institute for Fundamental Biomedical Research, and Department of Surgery, Johns Hopkins All Children's Hospital, and Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, St. Petersburg, FL, USA.
Fumiaki KanamoriCancer and Blood Disorders Institute, Institute for Fundamental Biomedical Research, and Department of Surgery, Johns Hopkins All Children's Hospital, and Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, St. Petersburg, FL, USA.
Krisztian CsomosDivision of Pediatric Allergy/Immunology, University of South Florida at Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.ORCID http://orcid.org/0000-0002-9266-1089
Tomoko StanselCancer and Blood Disorders Institute, Institute for Fundamental Biomedical Research, and Department of Surgery, Johns Hopkins All Children's Hospital, and Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, St. Petersburg, FL, USA.
Nobuyoshi HiraokaDivision of Pathology and Clinical Laboratories, National Cancer Center Hospital; Division of Molecular Pathology, Analytical Pathology, National Cancer Center Research Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4215-4385
Masayuki YoshidaDivision of Pathology and Clinical Laboratories, National Cancer Center Hospital; Division of Molecular Pathology, Analytical Pathology, National Cancer Center Research Institute, Tokyo, Japan.
Jolan WalterDivision of Pediatric Allergy/Immunology, University of South Florida at Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.ORCID http://orcid.org/0000-0002-6192-0703
Carl F WareLaboratory of Molecular Immunology, Infectious and Inflammatory Diseases Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-5006-418X
Masanobu KomatsuCancer and Blood Disorders Institute, Institute for Fundamental Biomedical Research, and Department of Surgery, Johns Hopkins All Children's Hospital, and Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, St. Petersburg, FL, USA. mkomats1@jhmi.edu.ORCID http://orcid.org/0000-0001-7548-137X

Funding

Normalization of tumor vasculature by R-RasR01CA125255 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI KOMATSU, MASANOBU · 2008 to 2018
$4.2M
Role of intratumoral high endothelial venules in tumor immunityR01CA251192 · NCI · JOHNS HOPKINS UNIVERSITY · PI Masanobu Komatsu · 2022 to 2026
$1.8M
Florida Department of Health 20B01NCI NIH HHS R01 CA125255NCI NIH HHS R01 CA251192U.S. Department of Defense (United States Department of Defense) W81XWH2211051
6 · The paper itself

Abstract

B cell-rich tertiary lymphoid structures (TLS) are associated with favorable prognosis and positive response to immunotherapy in cancer. Here we show that simultaneous activation of innate immune effectors, STING and lymphotoxin-β receptor (LTβR), results in CD8

Indexed as

B-LymphocytesLymphotoxin beta ReceptorMembrane ProteinsTertiary Lymphoid StructuresAnimalsCD8-Positive T-LymphocytesFemaleLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutSTING ProteinLymphotoxin beta ReceptorMembrane ProteinsSting1 protein, mouseSTING Protein

Identifiers

PMID40897896
PMCPMC12479350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.